Five-year FFP and 5-year OS rates according to IPFP scores
| IPFP score . | Number of patients (%) . | BCCA 5-y FFP, % . | IPFP report 5-y FFP, % . | BCCA 5-y OS, % . | IPFP report 5-y OS, % . |
|---|---|---|---|---|---|
| 0 | 48 (8.3) | 83 ± 6 | 84 ± 4 | 98 ± 2 | 89 ± 2 |
| 1 | 166 (28.7) | 86 ± 3 | 77 ± 3 | 97 ± 2 | 90 ± 2 |
| 2 | 157 (27.1) | 80 ± 3 | 67 ± 2 | 92 ± 2 | 81 ± 2 |
| 3 | 109 (18.8) | 74 ± 4 | 60 ± 3 | 87 ± 4 | 78 ± 3 |
| 4 | 62 (10.7) | 67 ± 6 | 51 ± 4 | 85 ± 5 | 61 ± 4 |
| ≥5 | 37 (6.4) | 66 ± 8 | 42 ± 5 | 74 ± 8 | 56 ± 5 |
| Reference | 7 | 42 | 7 | 42 |
| IPFP score . | Number of patients (%) . | BCCA 5-y FFP, % . | IPFP report 5-y FFP, % . | BCCA 5-y OS, % . | IPFP report 5-y OS, % . |
|---|---|---|---|---|---|
| 0 | 48 (8.3) | 83 ± 6 | 84 ± 4 | 98 ± 2 | 89 ± 2 |
| 1 | 166 (28.7) | 86 ± 3 | 77 ± 3 | 97 ± 2 | 90 ± 2 |
| 2 | 157 (27.1) | 80 ± 3 | 67 ± 2 | 92 ± 2 | 81 ± 2 |
| 3 | 109 (18.8) | 74 ± 4 | 60 ± 3 | 87 ± 4 | 78 ± 3 |
| 4 | 62 (10.7) | 67 ± 6 | 51 ± 4 | 85 ± 5 | 61 ± 4 |
| ≥5 | 37 (6.4) | 66 ± 8 | 42 ± 5 | 74 ± 8 | 56 ± 5 |
| Reference | 7 | 42 | 7 | 42 |
A comparison of the 5-year outcome seen in 579 consecutive patients treated with ABVD for advanced-stage Hodgkin lymphoma at the BCCA and the projected outcome seen in patients included in the IPFP.